Tacrolimus for the Treatment of Ulcerative Colitis.
- Author:
Katsuyoshi MATSUOKA
1
;
Eiko SAITO
;
Toshimitsu FUJII
;
Kento TAKENAKA
;
Maiko KIMURA
;
Masakazu NAGAHORI
;
Kazuo OHTSUKA
;
Mamoru WATANABE
Author Information
- Publication Type:Review
- Keywords: Tacrolimus; Colitis, ulcerative; Cyclosporine; Calcineurin inhibitors
- MeSH: Antibodies; Calcineurin; Colectomy; Colitis, Ulcerative*; Cyclosporine; Follow-Up Studies; Humans; Infliximab; Necrosis; Opportunistic Infections; Pneumonia, Pneumocystis; Prognosis; Tacrolimus*
- From:Intestinal Research 2015;13(3):219-226
- CountryRepublic of Korea
- Language:English
- Abstract: Tacrolimus is a calcineurin inhibitor used for the treatment of corticosteroid-refractory ulcerative colitis (UC). Two randomized controlled trials and a number of retrospective studies have assessed the therapeutic effect of tacrolimus in UC patients. These studies showed that tacrolimus has excellent short-term efficacy in corticosteroid-refractory patients, with the rates of clinical response ranging from 61% to 96%. However, the long-term prognosis of patients treated with tacrolimus is disappointing, and almost 50% of patients eventually underwent colectomy in long-term follow-up. Tacrolimus can achieve mucosal healing in 40-50% of patients, and this is associated with a favorable long-term prognosis. Anti-tumor necrosis factor (TNF)-alpha antibodies are another therapeutic option in corticosteroid-refractory patients. A prospective head-to-head comparative study of tacrolimus and infliximab is currently being performed to determine which treatment is more effective in corticosteroid-refractory patients. Several retrospective studies have demonstrated that switching between tacrolimus and anti-TNF-alpha antibody therapy was effective in patients who were refractory to one of the treatments. Most adverse events of tacrolimus are mild; however, opportunistic infections, especially pneumocystis pneumonia, are the most important adverse events, and these should be carefully considered during treatment. Several issues on tacrolimus treatment in UC patients remain unsolved (e.g., use of tacrolimus as remission maintenance therapy). Further controlled studies are needed to optimize the use of tacrolimus for the treatment of UC.
